Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Royalties and manufacturing revenues from Wyeth's Alavert expected to be major contributor to sales growth for fast-dissolve technology firm in 2003. Loratadine product "should end up this year [contributing] about 10% of our total revenues," President & CEO John Seibert, PhD, said during Feb. 20 analysts call. He noted Wyeth is "looking at this as the largest OTC product introduction in their history, and these are the people that brought you Advil." CIMA signed an exclusive supply agreement with Wyeth last June; Alavert employs CIMA's DuraSolv technology (1"The Tan Sheet" July 22, 2002, In Brief). Seibert estimated OTCs using CIMA technology account for 25% to 30% of the firm's revenues. CIMA's Q4 sales grew 68.5% to $15.5 mil., while annual sales rose 45.6% to $46.6 mil...

Related Content

Wyeth OTC loratadine “approvable”





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts